Effects of gonadectomy on prolactin and LH secretion and the pituitary–thyroid axis in male dogs

An investigation on the relevance of prolactin, insulin-like growth factor-1 and 25-hydroxyvitamin D3 (25-OHD3 ) in canine benign prostatic hyperplasia in a predisposed breed model

Serum concentrations of prolactin (PRL), insulin-like growth factor-1 (IGF-1) and 25 hydroxyvitamin D₃ (25-OHD₃ ) were analysed to investigate their possible involvement in the pathogenesis of benign prostatic hyperplasia (BPH). For this, dogs of the Rhodesian Ridgeback (RR) breed were used because of a verified breed disposition for the development of BPH. Labrador Retrievers (LR) served as controls. The prostate gland status was characterised by the prostate gland volume, clinical signs of BPH (haemospermia and sonographic findings) and the plasma concentration of canine prostate-specific arginine esterase (CPSE). Breed specificity in the RR was expressed by a correlation of PRL with breed (p < 0.05). Similar relationships existed in the dogs with normal CPSE (CPSEn) with respect to the IGF-1 concentrations (LR: p < 0.05). The latter were negatively correlated with prostatic volume and age (both p < 0.05). Concentrations of 25-OHD₃ were tendentially (p = 0.18) lower in the RR with increased CPSE (CPSEi) compared with the CPSEn LR and RR showing clinical signs of BPH. A negative correlation between serum 25-OHD₃ and age (p < 0.05) existed in the CPSEi RR. Proof of 25-OHD₃ in prostatic secretion proved to be a breed specific feature in the RR (p < 0.0001). For all RR dogs showing clinical signs of BPH, a close to significant (p = 0.06) positive correlation with prostate gland volume was found. The results of the present study reveal no clear hints towards the significance of PRL and IGF-1 in the pathogenesis of canine BPH. In the RR breed there were indications of a causal relationship with age-dependent changes in the vitamin D metabolism. The data suggest the possibility of preventing or treating canine BPH by administering vitamin D or substances involved in the intraprostatic vitamin D metabolism.

[GnRH agonist implants in small animal practice - what do we know 13 years following EU registration?]

The availability of GnRH agonist implants offers the possibility of a reversible, temporary downregulation of endocrine and germinative testicular function in male dogs and hobs. This review provides an overview of the registered indication, the induction of temporary infertility in healthy, intact, sexually mature male dogs (4.7 and 9.4 mg deslorelin) and hobs (9.4 mg deslorelin) as well as various off-label indications. Off-label use requires strict indications, informed consent from the owner and a lack of licensed medication (safe and optimum effect). Off-label indications in the male dog include sexual-hormone dependant (disturbing) behavior, benign prostatic hyperplasia, small adenomas of the hepatoid glands and alopecia X. Successful use of deslorelin implants for estrus suppression in jils, but also for the treatment of hyperadrenocorticism in ferrets in general have been described. Similarly, hormonal castration can be induced in tomcats and queens. The variable time to onset of effect and its duration (extremely variable in some animals) represent a challenge for breeders. No (sufficient) contraceptive activity was identified in male rabbits and male guinea pigs; however, treatment did successfully suppress the estrus cycle in female individuals of these species, as well as reproductive activity in male and female rats. Regarding the use in birds and reptiles, significant species-specific differences exist with regard to efficacy, time until onset of effect and duration of downregulation. In birds, the implant is efficient to fully suppress egg laying in chicken, Japanese quail and psittacids. In doves, egg laying is only significantly reduced. Successful treatment of reproduction-associated (unwanted) behaviour patterns (feather picking, aggression) has also been described. In some male birds, namely zebrafinch and Japanese quail, the deslorelin implant is suitable to reduce testosterone levels. Successful treatment of hormone-dependent tumours (Sertoli-cell tumorus) in budgerigars has been described as well as the modulation of specific behavior in turkeys and an efficacy in facilitating their keeping (i. e. reduction of aggression). In reptiles, only the successful use of deslorelin in iguana has been demonstrated to date.

Kastration der Hündin – neue und alte Erkenntnisse zu Vor- und Nachteilen

Die Beratung von Hundehaltern bezüglich der Vorteile und Nachteile sowie des optimalen Zeitpunktes der Kastration einer Hündin ist komplex und sollte sich auf verlässliche Daten aus der Wissenschaft stützen sowie individuelle Belange berücksichtigen. Bei genauerer Betrachtung der aktuellen Publikationen zu diesem Thema fällt auf, dass einige lange für robust gehaltene Informationen etwas angepasst oder aktualisiert werden müssen. Ein offensichtlicher Vorteil der elektiven Kastration ist, dass Erkrankungen der Ovarien und sexualsteroidabhängige Erkrankungen wie Metropathien nicht auftreten. Weiterhin ist ein gewisser protektiver Effekt einer frühzeitigen Kastration auf die Entstehung von Mammatumoren anzunehmen, wenngleich dafür derzeit eine schwache wissenschaftliche Evidenz besteht und der Effekt vermutlich geringer ausfällt, als in einigen älteren Publikationen angegeben wurde. Die Kastration hat jedoch auch Nachteile. Als häufigste negative Folge wird seit Jahrzehnten die Harninkontinenz beschrieben. Aussagen zur Inzidenz sowie zu weiteren Einflussfaktoren, wie Kastrationszeitpunkt in Bezug zur Pubertät, sind jedoch uneinheitlich. Aktuell werden vor allem das gehäufte Auftreten verschiedener Tumorerkrankungen, die nicht direkt mit dem Reproduktionstrakt in Verbindung stehen, sowie ein höheres Risiko für Erkrankungen des Bewegungsapparats bei kastrierten Tieren diskutiert. Weitere Einflussfaktoren wie der Ernährungszustand des Hundes, Alter und/oder Haltung wurden jedoch häufig nicht erfasst. Die Datenlage zur Auswirkung der Kastration auf den Stoffwechsel und das Immunsystem der Hündin ist derzeit ungenügend. Wünscht der Tierbesitzer eine Kastration, bedarf es in jedem Fall einer eingehenden Beratung, die individuelle, rasse- und haltungsbezogene Aspekte einschließt. Derzeit ist eine Kastration am ehesten zwischen der ersten und zweiten Läufigkeit zu empfehlen, da ein gewisser protektiver Effekt auf die Entstehung von Mammatumoren anzunehmen ist und das Risiko unerwünschter Nebenwirkungen nach heutigem Wissensstand moderat ausfällt.

Altered Serum Thyrotropin Concentrations in Dogs with Primary Hypoadrenocorticism before and during Treatment

Background

Thyrotropin (TSH) can be increased in humans with primary hypoadrenocorticism (HA) before glucocorticoid treatment. Increase in TSH is a typical finding of primary hypothyroidism and both diseases can occur concurrently (Schmidt's syndrome); therefore, care must be taken in assessing thyroid function in untreated human patients with HA.

Objective

Evaluate whether alterations in cTSH can be observed in dogs with HA in absence of primary hypothyroidism.

Animals

Thirty dogs with newly diagnosed HA, and 30 dogs in which HA was suspected but excluded based on a normal ACTH stimulation test (controls) were prospectively enrolled.

Methods

cTSH and T4 concentrations were determined in all dogs and at selected time points during treatment (prednisolone, fludrocortisone, or DOCP) in dogs with HA.

Results

cTSH concentrations ranged from 0.01 to 2.6 ng/mL (median 0.29) and were increased in 11/30 dogs with HA; values in controls were all within the reference interval (range: 0.01–0.2 ng/dL; median 0.06). There was no difference in T4 between dogs with increased cTSH (T4 range 1.0‐2.1; median 1.3 μg/dL) compared to those with normal cTSH (T4 range 0.5‐3.4, median 1.4 μg/dL; P=0.69) and controls (T4 range 0.3‐3.8, median 1.8 μg/dL; P=0.35). After starting treatment, cTSH normalized after 2–4 weeks in 9 dogs and after 3 and 4 months in 2 without thyroxine supplementation.

Conclusions and Clinical Relevance

Evaluation of thyroid function in untreated dogs with HA can lead to misdiagnosis of hypothyroidism; treatment with glucocorticoids for up to 4 months can be necessary to normalize cTSH.

Androgens block outward potassium currents and decrease spontaneous action potentials in GH3 cells

Androgens produce nongenomic effects in several cells by different mechanisms, including ion channel modulation. Adenohypophyseal cells express several K(+) channels, including voltage and Ca(2+)-dependent K(+) (BK) channels, which might be the target of androgens to modulate cellular action potentials and hormonal secretion. Androgen effects were studied in GH3 cells (from anterior pituitary rat tumor) by means of the patch-clamp technique. Cells were continuously perfused with saline solution, in the absence or presence of the androgens studied, while applying 40 mV pulses of 400 ms from a holding potential of -60 mV in whole-cell configuration with nystatin-perforated patches. Androgens reversibly blocked noninactivating K(+) currents in a concentration-dependent manner without a latency period and with an order of efficacy of: 5β-dihydrotestosterone (DHT)>testosterone>5α-DHT. RT-PCR showed two isoforms of the α-pore forming subunits of BK channels. These channels are responsible for one third of the noninactivating current, according to the blockade of paxilline, a selective BK antagonist. Androgens seem to directly interact with BK channels since they were blocked in excised inside-out patches and independent of the whole-cell configuration and the NO-cGMP-dependent pathway. Testosterone, but not 5α- or 5β-DHT, increased BK currents in HEK-293 cells overexpressing the short isoform, suggesting a cellular selectivity based on the α-subunits. The effect on noninactivating currents may be responsible for the decrease of spontaneous action potential frequency. Long-term cellular incubation with testosterone did not modify noninactivating currents density in GH3 cells. It is remarkable that 5β-DHT, a reductase metabolite with weak androgenic activity, was the most efficient blocker.

Prolactin--to be reconsidered in canine mammary tumourigenesis?

Mammary tumours represent the most common neoplastic disease of the female dog, and the incidence in female dogs is much higher than in women. Whereas the influence of sexual steroids on breast cancer (BC) development in dogs has been studied, very little is known about the role of prolactin (PRL). New studies show that until recently, the importance of PRL in human BC development and progression has been highly underestimated. PRL plays a role in promoting benign as well as malignant neoplastic cell growth in BC in vitro and in vivo. Sporadic publications proposed a tumour promotor role in the dog. The goal of this review is to summarize our knowledge about PRL and human BC as well as canine mammary tumourigenesis, and propose future research in this area.

Endocrinology of obesity

Obesity is a growing health concern in humans and companion animals. Obesity is highly associated with various endocrine abnormalities that are characterized by hormonal imbalance and/or resistance. Weight reduction generally normalizes these endocrine alterations, implicating obesity as a direct cause. Most data in this area have been derived from obese humans, with little data pertaining to hormonal changes in obese dogs and cats. Because the literature contains inconsistent results and because considerable hormone-hormone interactions occur, we have a limited understanding of the obesity-induced changes on the endocrine system in dogs and cats.